The Correlation between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis (ox-LDL) in Centrally Obese Men

Priscilla Dian Ari; Ellis Susanti; Ilhamjaya Patellongi

doi:10.18585/inabj.v4i2.168

The Correlation between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis (ox-LDL) in Centrally Obese Men

Priscilla Dian Ari, Ellis Susanti, Ilhamjaya Patellongi

Abstract

BACKGROUND: Obesity is closely associated with atherosclerosis. Obesity and atherosclerosis are closely associated with inflammatory disease. Atherosclerosis constitutes a multifactorial disorder affecting the arterial wall, which is initiated by dyslipidemia and excerbated by inflammation. Plasma levels of lipoprotein-associated phospholipase A2 (Lp-PLA2) and oxidized low density lipoprotein (ox-LDL) have been identified as risk factors for cardiovascular disease. Lp-PLA2 is the sole enzyme responsible for the hydrolysis of oxidized phospholipids (oxPL) on LDL particles in atherosclerosis plaque. Plasma level of oxLDL is associated with inflammation and plays an important role in the development of atherosclerosis. The aim of this study was to assess the correlation between Lp-PLA2 and atherosclerosis (oxLDL) in centrally obese men.

METHODS: This was a cross-sectional study involving 71 men with central obesity with waist circumference >90 cm, aged 30-60 years old. Lp-PLA2 measurement was done by sandwich enzyme immunoassay. oxLDL measurement was done by ELISA method.

RESULTS: Results of this study showed that central obesity correlated positively with oxLDL (r=0.258; p=0.040) and Lp-PLA2 >422 ng/mL correlated positively with oxLDL (r=0.331; p=0.042).

CONCLUSIONS: We conclude that there is a correlation of Lp-PLA2 with atherosclerosis (oxLDL) in men with central obesity.

KEYWORDS: obesity, Lp-PLA2, oxLDL, atherosclerosis

Full Text:

PDF

References

Trayhurn P. Adipocyte biology. Obes Rev. 2007; 8 (suppl. 1): 41-4, CrossRef.

Engfeldt P, Arner P. Lipolysis in human adipocytes, effects of cell size, age and of regional differences. Horm Metab Res Suppl. 1988; 19: 26-9, PMID.

Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes. 2007; 56: 901-11, CrossRef.

Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, et al. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010; 375: 1536-44, CrossRef.

Ishigaki Y, Oka Y, Katagiri H. Circulating oxidized LDL: a biomarker and a pathogenic factor. Curr Opin Lipidol. 2009; 20: 363-9, CrossRef.

Grundtman C, Wick G. The autoimmune concept of atherosclerosis. Curr Opin Lipidol. 2011; 22: 327-34, CrossRef.

Galle J, Hansen-Hagge T, Wanner C, Seibold S. Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis. 2006; 185: 219-26, CrossRef.

Tsimikas S. Oxidized low-density lipoprotein biomarkers in atherosclerosis. Curr Atheroscler Rep. 2006; 8: 55-61, CrossRef.

Lyon CJ, Law RE, Hsueh WA. Minireview: Adiposity, inflammation, and atherogenesis. Endocrinology. 2003;144: 2195-200, CrossRef.

Jenny NS, Solomon C, Cushman M, Tracy RP, Nelson JJ, Psaty BM, et al. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study. Atherosclerosis. 2010; 209: 528-32, CrossRef.

Saenger AK, Christenson RH. Stroke biomarkers: progress and challenges for diagnosis, prognosis, differentiation, and treatment. Clin Chem. 2010; 56: 21-33, CrossRef.

Corsetti JP, Rainwater DL, Moss AJ, Zareba W, Sparks CE. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. Clin Chem. 2006; 52: 1331-8, CrossRef.

Vickers KC, Maguire CT, Wolfert R, Burns AR, Reardon M, Geis R, et al. Relationship of lipoprotein-associated phospholipase A2 and oxidized low density lipoproteinvin carotid atherosclerosis. J Lipid Res. 2009; 50: 1735-42, CrossRef.

Wrahle KWJ, Heys SD. Atherosclerosis: cell biology and lipoprotein. Curr Opin Lipidol. 2008; 19: 435-7, PMID.

Mohler ER, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent. J Am Coll Cardiol. 2008; 51: 1632-41, CrossRef.

O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) Trial. Circulation. 2006; 113: 1745-52, CrossRef.

Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE, et al. Lipoproteinassociated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study. Arch Intern Med. 2005; 165: 2479-84, CrossRef.

DOI: https://doi.org/10.18585/inabj.v4i2.168

Copyright (c) 2012 The Prodia Education and Research Institute